Sanofi’s Dupixent successor heads to regulators after Phase III success
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic …
Post
-
-
IGC Pharma adds New York site for Alzheimer’s disease trial
IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, …
-
Trial acceleration: AI supports progress, relationships drive success
Trial acceleration has been a topic of conversation for the pharmaceutical sector for years and as technology advances, it is …
-
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a …
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
-
Study finds no link between paracetamol use in pregnancy and autism risk
According to the World Health Organization, approximately one in 127 individuals worldwide had autism spectrum disorder (ASD) in 2021. ASD …
-
New data links eczema to inflammatory bowel and eye conditions
Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact …
-
Kardium unveils further pivotal trial results for Globe PFA system
Kardium has unveiled further results from the pivotal trial of its Globe Pulsed Field System, demonstrating the system’s success in …
-
BBH and PhaseWell partner for neuropsychiatric trials
Bio Behavioral Health (BBH) has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials. The collaboration …
-
Worldwide Clinical Trials to acquire Catalyst
Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. The transaction will …
-
Genespire to take rare disease gene therapy to clinic in 2026
Rare disease biotech Genespire is looking to take its single-dose gene therapy – GENE202 – to the clinic in 2026, …
-
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
IntraBio will head to regulators after its neurological rare disease drug met primary and secondary endpoints in a Phase III …
-
Free webinar: Ensuring compliance-first logistics for reliable clinical trials
According to GlobalData, industry-sponsored trials have increased from 7,721 in 2016 to 13, 685 in 2025. This growth over the …
-
Vibrent Health to join BARDA-funded clinical trial
Vibrent Health is set to join a hybrid/remote decentralised clinical research study funded by the Biomedical Advanced Research and Development …
